Hanall Biopharma

한올바이오파마 · 009420

Health Care Pharmaceuticals · KOSPI

Large-cap

Market cap US$2.1B (₩3T)

Overview

Hanall Biopharma is a South Korean pharmaceutical company that develops and supplies prescription medicines and biopharmaceutical treatments to patients and healthcare providers.

It is listed on KOSPI, Korea's main stock exchange. The filing's table of contents indicates the business spans both a domestic pharmaceutical operation and consolidated subsidiaries, suggesting a multi-entity corporate structure, though the filing text provided does not detail a single dominant product line.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$112.5M

▲ +11.7% YoY

Operating profit · FY2025

−US$663.6K

Turned to loss

Net income · FY2025

−US$4M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$97.8M(₩134.9B)	US$100.7M(₩138.9B)	US$112.5M(₩155.2B)
Operating profit	US$1.6M(₩2.2B)	US$167K(₩230.5M)	−US$663.6K(−₩915.8M)
Net income	US$2.5M(₩3.5B)	−US$1.3M(−₩1.8B)	−US$4M(−₩5.6B)

Revenue

FY2023US$97.8M
FY2024US$100.7M
FY2025US$112.5M

Operating profit

FY2023US$1.6M
FY2024US$167K
FY2025−US$663.6K

Net income

FY2023US$2.5M
FY2024−US$1.3M
FY2025−US$4M

Key ratios (FY2025)

ROE

-3.4%

Debt/Eq

39.3%

Op. margin

-0.6%

Net margin

-3.6%

Rev. YoY

▲ +11.7%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?